Texanik® | Tranexamic Acid

Home

Products

Oncology & Hematology Diseases

Texanik^®

Generic name: Tranexamic acid

Dosage form: 250 mg capsule

Pharmacological class: Antifibrinolytic agent

Indications:

This medication is used for the prevention and treatment of bleeding.

Texanik^® (tranexamic acid) is an antifibrinolytic agent that prevents and treats bleeding by inhibiting the breakdown of fibrin (a key clotting protein in blood) and stabilizing formed clots.

Reduction of heavy menstrual bleeding and any type of abnormal uterine bleeding
Prevention and treatment of bleeding during dental procedures in patients with bleeding disorders, including hemophilia or those receiving anticoagulant therapy
Reduction of postpartum hemorrhage
Management or reduction of various types of bleeding, including gastrointestinal bleeding, intracranial hemorrhage, or trauma-related bleeding
Prevention of hereditary angioedema
Prevention of bleeding following surgical procedures, including orthopedic and cardiac surgeries

Oral capsules, 250 mg

Use the medication exactly as prescribed by your physician. If you are unsure about the correct method of administration, consult your physician or pharmacist.

For optimal therapeutic outcomes, do not alter the dose or duration of treatment without medical advice.

Texanik^® may be taken with or without food.

If a dose is missed, take it as soon as you remember. If it is almost time for the next dose, skip the missed dose. Do not take a double or extra dose to compensate.

In case of overdose, immediately contact your physician or seek medical attention.

Visual function in treatments longer than 3 months
Signs of hypersensitivity reactions, seizures, and thrombotic events
EEG in patients with a history of seizures
Thromboelastography (TEG) or thromboelastometry (ROTEM) in patients with trauma-induced bleeding

Hypersensitivity to tranexamic acid or any of the excipients in the formulation

Patients with active thromboembolic disease such as deep vein thrombosis (DVT), cerebral thrombosis, or pulmonary embolism

Patients with a history of or risk factors for thrombosis or thromboembolism, including retinal vein or artery occlusion

Patients receiving combined hormonal contraceptives

Hematuria (blood in urine)

Tranexamic acid may cause dizziness and may impair physical or mental performance. Therefore, patients should avoid activities requiring high alertness, such as driving or operating heavy machinery, while taking this medication.

In patients with disseminated intravascular coagulation (DIC), tranexamic acid should be administered with caution and under close and continuous monitoring. Patients with a history of DIC should inform their physician.

Dose adjustment is required in patients with renal impairment. Patients with a history of kidney disease should inform their physician before starting treatment.

Tranexamic acid should be used with greater caution in patients with subarachnoid hemorrhage or untreated cardiovascular or cerebrovascular disease. Patients with a history of these conditions should inform their physician.

Any changes in vision, eye pain, or severe eye irritation during treatment should be reported to a physician immediately.

In case of severe hypersensitivity reactions such as erythema, swelling, blistering or skin detachment, or lesions in the eyes, mouth, throat, nose, or genital area, immediate medical attention should be sought.

Concurrent use of hormonal contraceptive methods should be avoided during tranexamic acid therapy.

Tranexamic acid crosses the placenta, and its concentration in the umbilical cord blood is similar to maternal plasma levels.

Tranexamic acid is excreted in breast milk. The decision to use this medication during lactation should be made after carefully weighing the benefits and risks.

Like all medicines, tranexamic acid may cause adverse effects, although not everybody gets them. The more common adverse effects include: